Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) are the two ligands of the Tie-2 receptor, a receptor tyrosine kinase that is expressed on the endothelium. A balanced angiopoietins/Tie-2 system is critical for the maintenance of vascular integrity. We investigated the potential role of a disrupted angiopoietins/Tie-2 system on hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Using streptozoticin (STZ) mice subjected to myocardial ischemia, we examined the effects of shifting the Ang-2/Ang-1 ratio on myocardial infarction size, apoptosis, bone marrow (BM)-endothelial progenitor cell (EPCs) differentiation and angiogenesis. In control mice, myocardial ischemia increased expression of both Ang-2 and Tie-2. In STZ mice, Ang-2 expression was elevated whereas Tie-2 expression was reduced and neither was significantly altered by ischemia. Myocardial infarct size and apoptosis were increased in STZ compared to control mice. Using in vivo administration of an adenovirus containing Ang-1 or Ang-2, we found that shifting the Ang-2/Ang-1 ratio to favor Ang-1 reduced myocardial apoptosis and infarct size in STZ mice, while shifting the Ang-2/Ang-1 ratio to favor Ang-2 resulted in a significant increase in myocardial infarct size and apoptosis in control mice. Myocardial ischemia-stimulated BM cell-EPC differentiation was inhibited and myocardial angiogenesis was reduced in STZ mice. Systemic administration of Ad-Ang-1 restored BM cell-ECP differentiation and increased myocardial VEGF expression and angiogenesis in STZ mice. Our data demonstrate that disturbed angiopoietin/Tie-2 signaling contributes to the hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Restoration of the Ang-2/Ang-1 ratio may be a novel therapeutic strategy for the treatment of diabetic myocardial ischemic diseases.